PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTelavancin
Vibativ(telavancin)
Vibativ (telavancin) is an unknown pharmaceutical. Telavancin was first approved as Vibativ on 2009-09-11. It is used to treat bacterial infections, infectious skin diseases, pneumonia, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial pneumonia and cross infection.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Vibativ (discontinued: Vibativ)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Telavancin hydrochloride
Tradename
Company
Number
Date
Products
VIBATIVCumberland PharmaceuticalsN-022110 RX2009-09-11
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
telavancin hydrochlorideNew Drug Application2012-12-12
vibativNew Drug Application2023-11-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pneumoniaEFO_0003106D011014—
bacterial infections—D001424A49
infectious skin diseases—D012874—
streptococcal infectionsEFO_1001476D013290—
staphylococcal infections—D013203A49.01
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Telavancin Hydrochloride, Vibativ, Cumberland
75316232027-01-01DP
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XA: Glycopeptide antibacterials
— J01XA03: Telavancin
HCPCS
Code
Description
J3095
Injection, telavancin, 10 mg
Clinical
Clinical Trials
17 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.91——1—2
Kidney diseasesD007674EFO_0003086N081——1—2
FibrosisD005355—————1—1
Cystic fibrosisD003550EFO_0000390E84———1—1
Chronic renal insufficiencyD051436—N18———1—1
HemorrhageD006470MP_0001914R58———1—1
Subarachnoid hemorrhageD013345EFO_0000713I60———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——32—16
Communicable diseasesD003141———32—16
BacteremiaD016470EFO_0003033R78.81—21——3
CellulitisD002481EFO_0003035L03.90—12——3
PneumoniaD011014EFO_0003106———2—13
Bacterial pneumoniaD018410EFO_1001272J15.9——2—13
Healthcare-associated pneumoniaD000077299————2——2
Staphylococcal skin infectionsD013207EFO_1001849L00——2——2
Infectious skin diseasesD012874————2——2
Staphylococcal infectionsD013203—A49.01——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gram-positive bacterial infectionsD016908——13——15
Bacterial infectionsD001424—A4911———2
Wound infectionD014946———1———1
AbscessD000038EFO_0003030——1———1
UlcerD014456MPATH_579——1———1
BurnsD002056—T30.0—1———1
SepsisD018805HP_0100806A41.9—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTelavancin
INNtelavancin
Description
Telavancin is a glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria. It has a role as an antibacterial drug and an antimicrobial agent. It is functionally related to a vancomycin.
Classification
Unknown
Drug classvancomycin-related compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O
Identifiers
PDB—
CAS-ID372151-71-8
RxCUI—
ChEMBL IDCHEMBL507870
ChEBI ID71229
PubChem CID3081362
DrugBank—
UNII IDXK134822Z0 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Vibativ – Cumberland Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Vibativ – Innoviva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,699 documents
View more details
Safety
Black-box Warning
Black-box warning for: Telavancin hydrochloride, Vibativ
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
205 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use